B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts
Immunological Reviews · 2026-05 · 339 (1)
DOI: 10.1111/imr.70124 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 24.04.2026. Verfasst von Sophieke Lems und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Atherosclerosis, B-Lymphocyte Subsets. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 334 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Leducq, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, NHLBI NIH HHS.
Abstract (Originalsprache)
Atherosclerotic cardiovascular disease (ASCVD) is increasingly recognized not just as a lipid‐driven disease, but as a complex interplay between vascular cells and the immune system. Accumulating evidence highlights a central, yet heterogeneous role for B cells in atherogenesis, with distinct subsets displaying opposing roles. In this review, we provide an in‐depth overview of the contributions of B cell subsets to ASCVD, including emerging insights into the roles and pathways of atheroprotective innate B cells producing IgM against oxidation‐specific epitopes (IgM OSE ) and newly appreciated age‐associated B cells (ABCs), a distinct subset that accumulates with aging and potentially exacerbates atherosclerosis. By integrating insights from preclinical models and human studies, we describe the mechanisms through which B cell subsets influence ASCVD, including antigen presentation and immune checkpoint‐mediated communication, secretion of cytokines and chemokines, and we highlight that humoral immunity in atherosclerosis reflects a context‐dependent interplay between antibody effector properties and antigenic targets rather than antibody class alone. Finally, we explore how the advances in our understanding of B cells may guide the development of more targeted immunomodulatory therapies that enhance atheroprotective B cell functions while limiting atherogenic responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
- Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia, USA.
- Division of Cardiovascular Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
ORCID-Profile: Sophieke Lems, Megan Grace Mazzei, Amanda C Foks, Coleen A McNamara
Förderung
- Fondation Leducq
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- NHLBI NIH HHS
- NIH HHS
- HORIZON EUROPE European Innovation Council
- National Institutes of Health
Zitieren
APA
Lems, S., Mazzei, M. G., Foks, A. C., & McNamara, C. A. (2026). B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts. Immunological Reviews, 339(1). https://doi.org/10.1111/imr.70124
Vancouver
Lems S, Mazzei MG, Foks AC, McNamara CA. B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts. Immunological Reviews. 2026;339(1). doi:10.1111/imr.70124
BibTeX
@article{Lems2026,
author = {Lems, Sophieke and Mazzei, Megan Grace and Foks, Amanda C and McNamara, Coleen A},
title = {B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts},
journal = {Immunological Reviews},
year = {2026},
volume = {339},
number = {1},
doi = {10.1111/imr.70124}
}
EUVIMED